Peptide Coalition: bremelanotide research peptide
A drug for desire has to contend with the difficulty of measuring desire. The trial results reward a closer look when their scales and limitations remain visible.
Stations
PT-141 and the BP141 spelling
PT-141 is the research designation for bremelanotide, a synthetic cyclic peptide related to alpha-melanocyte-stimulating hormone. The “BP141 peptide” spelling does not identify a separate compound in the references collected here. The US prescribing information identifies bremelanotide and its approved indication.
Bremelanotide was approved in the United States in June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Approval does not extend to men, postmenopausal women or sexual-performance enhancement. Material described as PT-141 research chemical sits outside that approval.
The molecule acts on central melanocortin receptors, chiefly MC4R, involved in sexual motivation. Its history grew out of a pigment-related peptide family. That shared biology also helps explain why skin darkening remains among the cautions.
RECONNECT desire scores
The two RECONNECT phase 3 trials enrolled 1,267 premenopausal women with hypoactive sexual desire disorder. Over 24 weeks, the integrated improvement in FSFI-desire was plus 0.35, while the integrated change in desire-related distress on FSDS-DAO item 13 was minus 0.33, both with P less than .001 against placebo.
These instruments ask about different aspects of sexual experience. I respect the measured improvement; the average effect still looks modest to me. A statistically detectable change still leaves room to argue about how much difference it makes to a person's life.
The 52-week open-label extension enrolled 684 women and reported sustained improvements without new safety signals. Nausea occurred in 40.4 per cent, flushing in 20.6 per cent and headache in 12.0 per cent. Continued follow-up adds information, though an open-label extension lacks the protection against expectation offered by a blinded placebo comparison.
MRI and hamster experiments
A randomised crossover fMRI study in 31 premenopausal women with HSDD reported increased sexual desire for up to 24 hours and altered brain processing of erotic stimuli, including enhanced amygdala-insula connectivity. This study earns its space by asking a narrower question: how central processing responds to melanocortin receptor activation.
In female Syrian hamsters, bremelanotide did not enhance sexual reward in a conditioned place-preference experiment and did not change melanocortin-receptor messenger RNA expression in the mesolimbic dopamine system. That animal finding complicates a simple reward-circuit explanation. It concerns a different experiment and endpoint from the human desire scales, so it gives the mechanism something to answer for without cancelling the human trials.
PT-141 adverse effects
The approved label warns about transient blood-pressure increases with a small fall in heart rate, and contraindicates use in uncontrolled hypertension or known cardiovascular disease. Skin and mucous-membrane darkening can occur and may not fully reverse. Pregnancy and breastfeeding safety are unsupported by controlled human evidence.
Nausea is a substantial tolerability cost in the long-term follow-up. Community accounts of stronger desire, arousal or closeness sit alongside accounts of no benefit, nausea, flushing and headache. Those descriptions are anecdotal reports, separate from clinical evidence, and much of the use described falls outside the approved population.
My verdict stays fairly narrow: a measurable, modest average benefit in the studied population, with a conspicuous burden of nausea and specific label restrictions. RECONNECT persuades me about its defined population; extending that judgement to everyone would be a guess.